KB-0742 Exhibits Tolerable Safety and Activity in Relapsed/Refractory Solid Tumors
November 17th 2023The selective CDK9 inhibitor KB-0742 displayed anti-tumor activity and manageable safety as a single agent in heavily pretreated patients with relapsed/refractory, transcriptionally addicted solid tumors, according to data from a phase 1 trial (NCT04718675).
Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid Tumors
November 9th 2023Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.
Phase 1 Trial Set to Explore Efficacy and Safety of KB-0742 in Solid Tumors
June 16th 2023Brian Van Tine, MD, PhD, discusses key considerations for understanding the biology of MYC, the rationale for the phase 1 study of KB-0742 in MYC-amplified or -overexpressed relapsed or refractory solid tumors, and patient characteristics that may signal their eligibility for participation in this trial.
Dr Van Tine on the Investigation of KB-0742 in R/R Solid Tumors
June 6th 2023Brian A. Van Tine, MD, PhD, discusses the ongoing evaluation of the CDK9 inhibitor KB-0742 in a phase 1 trial in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma, detailing the key enrollment criteria.
Novel CDK9 Inhibitor Looks to Expand Options in MYC-Amplified Solid Tumors and Non-Hodgkin Lymphoma
May 31st 2023Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.
Novel CDK9 Inhibitor Under Investigation in Solid Tumors and NHL
April 5th 2023Miguel Villalona-Calero, MD, discusses the unique mechanism of action of KB-0742 and the rationale and design of a phase 1 trial investigating the safety and efficacy of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.